BioMedNewsBreaks

FridayOct 16, 2026 3:40 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Highlights Insider Buying Alongside Its Integrated Healthcare Technology Strategy

Recent SEC Form 4 filings disclosed open-market purchases of Nano-X Imaging Ltd.’s (NASDAQ: NNOX) (“Nanox”) ordinary shares by CEO Erez Meltzer and Board Director Dan Suesskind, adding to purchases reported in recent months by Meltzer, Suesskind and Board Director Nogah Keinan. The transactions reflect share purchases made directly in the open market by the company’s senior leadership and board members, with additional details available in the respective SEC filings. This comes as Nanox continues to advance its integrated medical imaging and healthcare services platform, which combines proprietary digital X-ray technology, AI-powered imaging analytics, cloud-based software, remote radiology services and healthcare…

Continue Reading

FridayOct 16, 2026 2:18 pm

BioMedNewsBreaks — Nanox Imaging Ltd. (NASDAQ: NNOX) Subsidiary Signs Distribution Agreement to Commercialize HealthOST in Italy

Nanox (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with Tecnologie Avanzate, to commercialize its AI-powered bone health solution, HealthOST, in Italy. The agreement is intended to expand Nanox AI commercial presence in the Italian market, leveraging Technologic experience and local market knowledge. HealthOST analyzes eligible routine CT scans to provide qualitative and quantitative assessments of the spine, helping clinicians identify patients who may benefit from further evaluation for musculoskeletal conditions such as osteoporosis. To view the full press release, visit https://ibn.fm/y9Zro About Nanox Nanox (NASDAQ:…

Continue Reading

FridayOct 16, 2026 1:47 pm

BioMedNewsBreaks — Nanox Imaging Ltd. (NASDAQ: NNOX) Nanox.ARC X Named One of TIME Best Inventions of 2026

Nanox (NASDAQ: NNOX), a medical imaging technology company, announced that its Nanox.ARC X digital tomosynthesis system has been named one of TIME's Best Inventions of 2026. The U.S. Food and Drug Administration-cleared system captures X-ray images from multiple angles, generating up to 200 coronal images per scan to produce three-dimensional views of the body at up to 80% less radiation than computed tomography ("CT") for equivalent body parts. Designed with a smaller footprint than conventional CT systems, Nanox.ARC X operates using a standard 110-volt power outlet and features simplified installation, operator workflows and remote upgrade capabilities. The company plans to…

Continue Reading

FridayOct 16, 2026 12:30 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Aon Review Supporting Estimated Annual Healthcare Cost Savings of 2.5% to 7.2%

DarioHealth (NASDAQ: DRIO) announced results of a review conducted by the Managed Care Services Team of Aon plc evaluating the clinical and financial impact of its AI-powered chronic condition management services. Based on data and studies provided or identified by DarioHealth, Aon concluded that the evidence supports estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population, equivalent to approximately $3.8 million to $10.8 million annually for a representative population of 20,000 covered lives. Aon also estimated that management of multiple conditions and access to physicians, which were excluded from the initial calculations, could contribute an additional…

Continue Reading

ThursdayOct 15, 2026 3:48 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advances Expansion Plans with Meduvo and Zoolzy Acquisitions, Uplisting

Earth Science Tech (OTCQB: ETST), a healthcare, pharmacy, and telemedicine holding company, uplisted to the OTCQB Venture Market on Sept. 17, 2026, marking a key milestone in its fiscal 2027 growth strategy. The move follows a strong first quarter, with revenue increasing 3% to $9.0 million and net income rising 57% to $715,697, alongside acquisitions of Meduvo LLC, a compounding pharmacy, and Zoolzy LLC, a pharmaceutical distributor that expands the company’s opportunities in human therapeutics and animal health. At its Aug. 31 annual shareholder meeting, investors also approved measures supporting potential future uplisting to the Nasdaq or NYSE, the planned…

Continue Reading

WednesdayOct 14, 2026 3:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, received U.S. Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application for Lucid-MS, clearing the way for Phase 2 clinical testing of its multiple sclerosis (“MS”) candidate. The planned randomized, double-blind, placebo-controlled study will evaluate the drug’s efficacy, safety and tolerability in patients with MS, with researchers assessing clinical symptoms and changes visible through brain imaging. Unlike many existing MS therapies that target the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage,…

Continue Reading

WednesdayOct 14, 2026 2:40 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Strengthens UK Market Access and Hospital-Based AI Capabilities

Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”), an innovative technology company, is advancing Nanox.AI’s commercial and technology strategy through two developments aimed at expanding the use of AI in medical imaging. An exclusive three-year reseller agreement with Vertec Scientific, including minimum annual license commitments, establishes a dedicated UK channel for HealthOST, an AI-powered software solution that delivers qualitative and quantitative analysis of spinal CT images to help clinicians evaluate and assess spinal musculoskeletal disease, including osteoporosis. Separately, Nanox.AI has optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO, demonstrating the potential to run AI inference locally on hospital…

Continue Reading

WednesdayOct 14, 2026 10:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Completes Manufacturing of Next-Generation AI Intoxication Detection Kiosk

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, announced the completion of manufacturing for its next-generation Edge AI Intoxication Detection Kiosk. The new hardware builds on a prototype developed in June and is designed to support the company's proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment. MindBio is continuing software integration, system testing and validation of its predictive models against conventional breath alcohol and oral fluid…

Continue Reading

TuesdayOct 13, 2026 9:50 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Florida Healthcare Network With New PharmcoRx Pharmacy in Jacksonville

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions, announced the opening of a new PharmcoRx community pharmacy in Jacksonville, Florida, expanding its healthcare operations in the state. Located across from HCA Florida Memorial Hospital, the new facility offers prescription fulfillment, medication management, same-day delivery, specialty pharmacy services and patient support. The location also provides higher-margin contracted services for healthcare providers and institutions, including participants in the federal 340B drug pricing program, long-term care facilities and government agencies. PharmcoRx currently operates a network of six retail pharmacies across Florida. The expansion supports NextPlat's…

Continue Reading

TuesdayOct 13, 2026 9:10 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response. Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active…

Continue Reading